Cure’s Medtech Funding Tracker 2026

For biotech deals, visit our Biotech Funding Tracker, updated weekly.

August 2026

Wellinks

Date: August 4, 2026 Series: Series B Amount: $10M Therapeutic area: Cardiopulmonary remote patient monitoring/chronic disease management Modality: Spire Remote Patient Monitoring (RPM) System that combines passive wearable health tags with predictive analytics that identify early physiologic changes associated with clinical deterioration. Notable Investors: UMass Memorial Health/UMMH

Based out of New Haven, Connecticut, the company announced that it closed $10 million to fund commercial growth to build on its multiyear relationship with UMass Memorial Health and other partners to accelerate the expansion of the company’s predictive care solution. Wellinks plans to expand commercial footprint into rural and underserved markets, advance predictive analytics engines, extend care model into Congestive Heart Failure, and grow patient access to its predictive care model.

July 2026

SoundHealth

Date: July 30, 2026 Series: Series A (oversubscribed) Amount: $12.25M Therapeutic area: Nasal congestion, allergic/non-allergic rhinitis, and sleep-related breathing disorders Modality: FDA-cleared AI-powered wearable device used to treat allergic and non-allergic rhinitis. Notable Investors: Shangbay Capital; Moai Capital; J4 Ventures; TeleSoft Partners

 Located in Los Altos, California, SoundHealth announced that it closed an oversubscribed Series A round to bring its total venture funding to $12.25M. The company plans to use the funds to improve its growth trajectory for its FDA-cleared wearable device, Sonu, which is an alternative to corticosteroid nasal sprays used for allergic and non-allergic rhinitis. The device delivers targeted acoustic vibrational waves via the wearable band that stimulate autonomic nerve pathways and increase nitric oxide release in the nasal mucosa, reducing tissue swelling and congestion. In addition to Sonu, the company also makes Spatial Sleep, a personalized acoustic device for sleep onset and duration.

CoreMap

Date: July 29, 2026 Series: Series C (oversubscribed) Amount: $37M Therapeutic area: Cardiology Modality: Proprietary high-density electrophysiology (EP) mapping system combining micro-electrode catheter technology with advanced data analytics and novel algorithms for AFib ablation mapping. Notable Investors: Medtronic; unnamed existing and new investors

Based in Burlington, Massachusetts, CoreMap announced that it closed an oversubscribed $37 million Series C financing round, led by Medtronic. The company said the investment will help accelerate getting its next-generation AFib mapping platform to market. The company’s device allows AFib ablation guidance for doctors based on large data sets of highly accurate electrical activation data.

Epitel

Date: July 28, 2026 Series: Series B Amount: $26M Therapeutic area: Neurology/seizure detection and diagnosis Modality: Wearable wireless sensor system with integrated AI-driven event detection that enables extended-duration at-home EEG monitoring of brain activity for weeks at a time. Notable Investors: Catalyst Health Ventures; Genoa Ventures

Based in Salt Lake City, Utah, Epitel announced the closing of a $26 million Series B financing that will be used to further market its REMI Remote EEG Monitoring System, which provides wireless EEG monitoring with AI capabilities to detect neurological occurrences like seizures remotely. The device is FDA cleared for patients one years old and older. The company plans to also use funds to streamline hospital and clinic deployment models and accelerate ambulatory/home monitoring market access.

Throne Science

Date: July 28, 2026 Series: Series A Amount: $10M Therapeutic area: GI and colon cancer Modality: Sensor that attaches to any standard toilet and uses 12 computer vision models and AI to automatically track gut health, hydration, and urinary function. Classified under FDA’s General Wellness framework — meaning it is a wellness monitoring tool, not a diagnostic device, and cannot make diagnostic or treatment claims. Notable Investors: Will Ventures; Emerson Collective; Workshop, LEAD VC; Salt VC; Accomplice; Moxxie; Ventures Together; Symphony; Felix Capital; Cosmic Venture Partners; Offscript; V1.VC; and Morrison Seger

Based in Austin, Texas, Throne Science announced the closing of a $10 million Series A funding round. The company plans to use the funds to expand its team and advance R&D efforts for the next generation of the device that is aimed at detecting colon cancer and other life-threatening conditions.

CARPL.ai

Date: July 23, 2026 Series: Series A Amount: $10M Therapeutic area: Radiology Modality: Radiology AI / medical imaging Notable Investors: International Finance Corporation (arm of the World Bank Group); Stellaris Venture Partners; additional undisclosed investors

Based in San Francisco, California, the company announced that it raised $10 million in a Series A round. The company’s technology platform is used by the governments including India, Brazil, Singapore, Spain, and the UAE. It will use the funds to strengthen technology infrastructure, accelerate product development, expand global sales and delivery teams, and grow partner ecosystem and commercial presence across North America, Latin America, Europe, Asia-Pacific, and emerging markets.

TYBR Health

Date: July 21, 2026 Series: Series A Amount: $30M Therapeutic area: Orthopedics Modality: Flowable extracellular matrix hydrogel designed to protect tendons, ligaments, muscles, and surrounding soft tissue while they heal after surgery. Notable Investors: Vensana Capital; Mutual Capital Partners; Neovate Capital Partners

Houston, Texas-based TYBR Health announced a $30 million Series A financing to expand commercial access to its B3 GEL System, an FDA-cleared flowable extracellular matrix hydrogel designed to protect tendons, ligaments, muscles, and surrounding soft tissue while they heal after surgery. The funds will also be used to broaden product indications and fund clinical studies evaluating tissue protection during orthopedic surgery. Because B3 GEL is already being used across multiple procedure types, this financing is to push for it to be a repeatable part of surgical practice.

RapidPulse

Date: July 16, 2026 Series: Series B (oversubscribed) Amount: $48M Therapeutic area: Neurovascular / acute ischemic stroke treatment Modality: Aspiration catheter platform for mechanical thrombectomy that is designed to improve clot removal efficiency and procedural consistency for physicians treating acute ischemic stroke Notable Investors: Medtronic; TechWald Next S.p.A.; S3 Ventures; SBI Investment Company Ltd.; Florida Opportunity Fund; Santé Ventures; Syntheon; Hatteras Venture Partners; Epidarex Capital

Headquartered in Miami, Florida, RapidPulse announced that it closed $48 million Series B financing. The company plans to use the funds for its ongoing Investigational Device Exemption study called TURBO (Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions).RapidPulse also will put money toward its patented and proprietary technology platform that includes a line of catheter sizes and to pursue FDA approval pending data.

410 Medical

Date: July 14, 2026 Series: Growth Round Amount: $12M Therapeutic area: Emergency and critical care resuscitation Modality: LifeFlow, an FDA-cleared rapid infusion device designed to help clinicians quickly deliver fluid and blood products to patients experiencing sepsis, hemorrhagic shock, and other life-threatening conditions where speed of resuscitation is critical. Notable Investors: Orlando Health Ventures; Hatteras Venture Partners; Ballad Health; OSF Healthcare; Rex Health Ventures; CU Healthcare Innovations Fund; Sarnova

Durham, North Carolina-based 410 Medical announced the completion of a $12 million financing round. The company plans to use the funds to scale commercial operations and fund the launch of its next-generation LifeFlow infuser in 2027. The LifeFlow products are used by more than 500 hospitals and EMS agencies across the country and the company believes big support from health systems signals strong clinical validation moving forward.

June 2026

GT Medical Technologies

Date: June 9, 2026 Series: Series E Amount: $100M Therapeutic area: Brain tumors  Modality: Radiotherapy implant Notable Investors: Viking Global Investors, MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, FemHealth Ventures

Tempe, Ariz.-based GT Medical Technologies oversubscribed $100 Million Series E equity financing to advance commercial treatment for patients with operable brain tumors with its GammaTile, an FDA-cleared bioresorbable radiotherapy implant placed directly into the brain tumor cavity during surgery. The capital will fund commercial expansion and the BRIDGES trial for newly diagnosed glioblastoma patients. The company’s ROADS randomized trial that was presented at the 2026 ASCO conference showed GammaTile reduced tumor recurrence risk by 93% and death risk by 41% at 12 months versus standard care.

CereVasc

Date: June 4, 2026 Series: Series C Amount: $85M Therapeutic area: Neurology / normal pressure hydrocephalus (NPH) Modality: eShunt System, a minimally invasive endovascular implant Notable Investors: Piper Sandler Merchant Banking; Johnson & Johnson Innovation; Medtronic; Bain Capital Life Sciences; Perceptive Xontogeny Venture Funds

 Based in Boston, Mass., CereVasc announced that it completed the initial closing of an $85 million Series C financing. Proceeds will fund ongoing clinical and regulatory development of the company’s eShunt System, including the ongoing STRIDE pivotal trial in patients with Normal Pressure Hydrocephalus, an underdiagnosed and undertreated condition. Commercialization is targeted for 2028.

Advanced NanoTherapies (ANT)

Date: June 2, 2026 Series: Series B Amount: $31M+ (oversubscribed) Therapeutic area: Cardiovascular Modality: Device plus drug combination Investors: Undisclosed strategic investor and S3 Ventures (co-leads), T45 Fund, new and existing investors

Santa Clara, Calif.-based ANT announced the closing of an oversubscribed Series B financing totaling more than $31 million. The company is developing a dual-drug nanoparticle-coated balloon (DCB) platform called SirPlux Duo, which delivers both paclitaxel and sirolimus for treatment of coronary and peripheral artery disease. The technology is exclusively licensed from Cleveland Clinic and has received FDA breakthrough designation but is not yet approved for commercial use.

May 2026

Signos

Date: May 27, 2026 Series: Not disclosed Amount: $20M Therapeutic area: Metabolic health, weight management Modality: FDA-cleared AI-powered continuous glucose monitoring (CGM) system Notable Investors: Google Ventures, Dexcom, Blue Cross Blue Shield of Alabama

Signos, of Palo Alto, Calif., raised $20 million in a funding round. As part of the partnership with Dexcom, this co-investment between the companies will include a new distribution deal to put Signos’ subscription plans on Dexcom’s direct-to-consumer site, Stelo.com. Signos’ AI app processes glucose data from Dexcom’s Stelo biosensor and provides insights into a user’s metabolic patterns, including how food affects their glucose levels.

Vortex Imaging

Date: May 18, 2026 Series: Financing round Amount: $12M Therapeutic area: 3D body scans Modality: Ultrasound Investors: 10D Ventures, Entrée Capital, Harel T.E.C Partnership, Connecticut Innovations, PhiFund Ventures

Sunnyvale, Calif., and Givatayim, Israel, based Vortex Imaging Raised $12 Million to accelerate FDA clearance and support of continued development, regulatory clearance, and commercialization of its computational ultrasound system. The system is designed to enable high-quality 3D volumetric imaging using pioneering computational image reconstruction technology that utilizes GPUs-on-Cloud.

Butterfly Medical

Date: May 14, 2026 Series: Series C Amount: $21M Therapeutic area: Benign Prostatic Hyperplasia (BPH) Modality: Implantable device Investors: European Innovation Council (EIC), Junson Capital, MedVenture, New Rhein Healthcare Investors

Based in Boston, Mass., and Yokneam, Israel, Butterfly Medical  secured $21 Million in upsized Series C funding to advance its minimally Invasive BPH treatment, which is designed to alleviate the common and debilitating symptoms of BPH. The device already secured CE Mark approval for use in Europe, and is a minimally invasive, implantable solution that mechanically retracts the lateral lobes of the prostate to restore urine flow. It is made to restore and maintain natural urinary flow without the need for cutting, burning or removing tissue, while also being fully reversible.

BlueWind Medical

Date: May 14, 2026 Series: Financing worth $47.8 million in a combination of equity and debt Amount: $47.8 Million Funding Round Therapeutic area: Urgency urinary incontinence (UUI) Modality: Implantable, wearable neuromodulation medical device Investors: Not disclosed

Salt Lake City-based BlueWind closed $47.8 million in financing through a combination of equity and debt. The company will use the proceeds for commercialization and scaling of its Revi System, which is an Implantable Tibial Neuromodulation (ITNM) device used to treat UUI. The device delivers targeted stimulation to the posterior tibial nerve through a lightweight, external wearable. Implanted Revi is done in an outpatient setting and requires local anesthesia.

Urologic Health Inc.

Date: May 14, 2026 Series: Seed Amount: $11 Million Therapeutic area: Bladder dysfunction Modality: Non-invasive urodynamics platform Investors: Edge Medical Ventures, SHD Partners, Longevity Venture Partners

Based in Jersey City, N.J., and Or Yehuda, Israel, Urologic Health closed $11 Million seed financing to advance its niu System, a non-invasive bladder function monitoring device that provides data on conditions such as overactive bladder, urinary retention, and incontinence without catheterization. The funding will go toward the company’s clinical validation, FDA 510(k) regulatory pathway, and initial U.S. commercialization efforts.

Rivermark Medical

Date: May 13, 2026 Series: Series D Amount: $20M Therapeutic area: Benign prostatic hyperplasia (BPH) Modality: Endourethral stent system or prostatic stent Investors: Andera Partners

Based in Milwaukee, Wis., Rivermark Medical raised $20M in Series D funding. The company plans to use the funds for its RAPID III clinical study for its FloStent system that treats men with lower urinary tract symptoms due to BPH. The study is analyzing the safety and efficacy of the stent. The company also intends to use the proceeds to commercialize FloStent when it becomes FDA approved.

UroMems

Date: May 13, 2026 Series: Strategic investment Amount: $60M Therapeutic area: Stress urinary incontinence (SUI) Modality: Implantable artificial urinary sphincter Investors: Ajax Health Fund I

Based out of Minneapolis, Minn., and Grenoble, France, UroMems raised a $60 million strategic investment for its large-scale clinical trials of the UroActive implant. The implant is the first smart automated artificial urinary sphincter (AUS) to treat SUI. 

April 2026

Axoft

Date: April 29, 2026 Series: Series A Amount: $55M Therapeutic area: Neurological disorders Modality: Implantable brain-computer interface Investors: C.P. Group Innovation, Alumni Ventures, Hillhouse Investment, Gaorong Ventures

Based in Cambridge, Mass., Axoft raised an oversubscribed $55 million Series A, bringing its total funding to more than $60 million. The company will use the capital to expand its clinical trials across the world and move forward U.S. regulatory approval of its implantable Brain-Computer Interfaces. Proceeds will also go toward helping to build a manufacturing practice facility to mass produce its implantable Brain-Computer Interfaces.

Nervonik

Date: April 27, 2026 Series: Series B Amount: $52.5M Therapeutic area: Chronic pain Modality: Peripheral nerve stimulation (PNS) therapy system Investors: Amzak Health, Foothill Ventures, Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, and Shangbay Capital

Los Angeles, Calif., based Nervonik closed an oversubscribed $52.5 million Series B financing. Funds will go toward development and commercialization of its PNS system, which provides real-time physiological feedback to enhance therapy personalization and efficacy. Early data about the system showed successful recording of evoked compound action potentials (ECAPs), which are neurophysiological biomarkers of nerve activation in response to a therapeutic electrical stimulus, and other biomarkers using implantable leads.

Cala Health

Date: April 20, 2026 Amount: $50 million Series: Growth Capital Therapeutic Area: Essential Tremor & Parkinson’s Modality: Wearable bioelectronic neuromodulation Investors: Trinity Capital

Cala Health secured $50 Million in growth capital to support commercial expansion of its FDA-cleared wearable tremor therapy, kIQ System. 

Pulnovo Medical

Date: April 19, 2026 Series: Strategic financing Amount: $100M Therapeutic Area: Pulmonary hypertension & heart failure Modality: Pulmonary Artery Denervation (PADN) Investors: Medtronic, EQT, Qiming Venture Partners, OrbiMed, Lilly Asia Ventures, Gaorong Ventures, HSG 

Based out of New York, Pulnovo Medical completed an oversubscribed $100 million strategic financing round. The company also entered into a commercial agreement with its lead investor Medtronic for future commercialization opportunities given Medtronic’s extensive global commercialization capabilities.

Sonire Therapeutics

Date: April 15, 2026 Series: Series A Amount: $18M Therapeutic area: Oncology Modality: High-intensity focused ultrasound (HIFU) therapy for pancreatic cancer Investors: Santé Ventures, Fast Track Initiative, SBI Investment, Nomura SPARX Investment

Palo Alto, Calif., -based Sonire Therapeutics completed $18M in Series A financing. The money raised will be use to accelerate clinical development, support U.S. regulatory progress following the company’s 2024 FDA Breakthrough Device Designation for its HIFU therapy system, which  enables precise, effective thermal ablation of tumors in an outpatient environment. The proceeds will also be used to advance global commercialization efforts for the company’s treatment.

Endovascular Engineering (E2)

Date: April 7, 2026 Series: Series C Amount: $80M Therapeutic Area: Pulmonary Embolism Modality: Mechanical thrombectomy medical device Investors: Gilde Healthcare, Norwest, Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments

Based in Menlo Park, Calif., E2  raised $80M to market its thrombectomy platform. The funds will support commercialization of the company’s Hēlo Thrombectomy Platform for the treatment of pulmonary embolism. The platform is indicated for the non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature. 

March 2026

Endogenx

Date: March 25, 2026 Amount: $138M Series: Series C Therapeutic Area: Type 2 diabetes Modality: Non-thermal pulsed electric fields Investors: Arboretum Ventures, more

Minneapolis, Minn., based Endogenx secured a $138 million Series C. The proceeds from this financing will go toward completing the company’s ReCET Clinical Study and support its path to FDA approval. The minimally invasive, outpatient endoscopic procedure uses non-thermal pulsed electric fields to treat inflamed tissue and support healthy cell regeneration in the first section of the small intestine. 

Science Corp

Date: March 5, 2026 Series: Series C Amount: $230 M Therapeutic Area: Neurological disorders Modality: Implantable brain-computer interface Investors: Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT, and Quiet Capital, pre-existing investors, and more

Alameda, California-based Science Corp closed a $230 million Series C financing. The capital will see the company through the commercialization of its brain-computer interface retinal implant, PRIMA. The funds will also go toward advancing the company’s core pipeline programs into the clinic.

February 2026

Avisi Technologies

Date: Feb 25, 2026 Series: Series A Amount: $10.7M capital raise Therapeutic area: Glaucoma Modality: Ophthalmic drainage implant Investors: MedVenture Partners, Sherpa Healthcare Partners, SNBL-Gemseki, SBI US Gateway Fund, Golden Seeds, and OneOneFive Good Growth Capital, Accanto Partners, Life Sciences Greenhouse Investment, Quaker Capital Investments

Based out of Redwood City, Calif., Avisi Technologies  closed $10.7M in new financing. The funds will go toward the company’s clinical trial SAPPHIRE, which received FDA IDE approval in 2025, and is analyzing the safety and efficacy of VisiPlate, which is a glaucoma treatment device engineered to sustainably reduce intraocular pressure by improving outflow of aqueous. The money raised will also be used to further development Avisi’s treatments for the entire spectrum of glaucomatous disease.

January 2026

Merge Labs

Date: January 15, 2026 Amount: $252M Series: Seed Round Therapeutic Area: Merge biological and artificial intelligence Modality: Brain-computer interface (BCI) platform Investors: Bain Capital, OpenAI

San Franciso, Calif., based Merge Labs, which is co-founded by OpenAI CEO Sam Altman, raised $252 million in a seed round. The proceeds will help accelerate the company’s work toward fusion of biological and artificial intelligence.

MedWatch Technologies

Date: January 14, 2026 Amount: $15 million Series: Series A Therapeutic Area: Diabetes Modality: Non-invasive wearable glucose monitor Investors: Stead Impact Ventures

Las Vegas, Nev.., based MedWatch Technologies, secured $15M Series A financing. The company will use the proceeds for the development of a non-invasive biosensor for glucose-related insight and its integrated lifestyle coaching platform.

Inquis Medical

Date: January 12, 2026 Amount: $75 million Series: Series C Therapeutic Area: Venous thromboembolic disease (VTE) Modality: Mechanical aspiration platform Investors: Undisclosed

Based in Menlo Park, Calif., Inquis Medical closed a $75 million Series C financing round. The proceeds will be used to accelerate commercial expansion of the Aventus Thrombectomy System across the country, as well as toward advancing the company’s next-generation product pipeline.

Ventaris Surgical

Date: Jan 9, 2026 Series: Series A Amount: $30M Therapeutic Area: Kidney stones Modality: Next-gen ureteroscopic system for kidney stone removal Investors: Longitude Capital, Vensana Capital, Atypical Ventures, Neotribe

Ventaris Surgical based out of San Carlos, Calif., completed a $30 million Series A financing round. The company is developing an ureteroscopic system designed to help surgeons achieve more complete stone clearance during kidney stone procedures. Proceeds from the funds will go toward clinical development and advancement of regulatory and commercial milestones.

Spiro Medical

Date: Jan 7, 2026 Series: Series A Amount: $67M Therapeutic Area: Pulmonary Modality: Implantable neuromodulation system for asthma Investors: Andera Partners, Omega Funds, Sherpa Healthcare Partners, HSG (Hong Kong), Supernova Invest (Paris), Northern Light Venture Capital, and Hero Inc. Ltd UK

Spiro Medical, based out of Irvine, Calif., closed a $67 million Series A equity financing round. The company plans to use the funds from the financing to develop a purpose-built Pulmonary Neuromodulation System (PNM) for the treatment of Asthma, and to execute on the clinical work required for regulatory approval in the United States.